

1 Continuous Bayesian Variant Interpretation
2 Accounts for Incomplete Penetrance among
3 Mendelian Cardiac Channelopathies

4
5
6 Supplemental Material
7

8
9 **Supplemental Methods**

10
11 **Supplemental Table 1.** Covariate Statistical Associations.
12

13 **Supplemental Figure 1.** Observed and empirical penetrance by residue.

14 **Supplemental Figure 2.** Coverage plots for *KCNQ1*-LQT1 model.

15 **Supplemental Figure 3.** Coverage plots for *SCN5A*-LQT3 model.
16
17

18 **Supplemental Methods**

19 *Appraisal of Literature Data.* The presence of absence of a clinical diagnosis of LQTS was
20 defined by a Schwartz score¹ ≥ 3.5 or a single QT interval ≥ 480 ms³. Affected status of LQT1
21 was annotated in compliance with the diagnostic guidelines published by the
22 HRS/EHRA/APHRS Expert Consensus Statement on the Management of inherited
23 Arrhythmias², withholding point contributions from genotype-positive status. In literature reports
24 where patient level data was not available for manual review, the status was assigned in
25 accordance with that reported by the authors. The *KCNQ1* transcript ENST0000155840 was
26 used to map all variants. PubMed was searched for the term “KCNQ1” and identified a total of
27 2216 manuscripts, of which 326 provided sufficient information to interpret meaningful clinical
28 phenotypes. Each paper was manually reviewed for LQT1 status in affected and unaffected
29 individuals (described below). The full set of heterozygotes for variants in *KCNQ1* from gnomAD
30 was added to this curation. All individuals from gnomAD were assumed not to have LQT1, an
31 assumption previously shown not to alter the model performance^{3,4}. From the literature and
32 gnomAD X heterozygotes for XXX unique missense or in-frame insertion/deletion (indel)
33 variants were identified. The *SCN5A* transcript ENST00000333535 was used to annotate all
34 variants. For *SCN5A*-LQT3, a previously reported dataset was queried for association with
35 LQTS⁴. This comprised 86118 heterozygotes with 1667 unique missense or in-frame
36 insertion/deletions.

37

38 *Collation of Cohort Data.* Three international centers with arrhythmia genetics expertise
39 contributed clinical phenotypes and genotypes for *KCNQ1* probands and family members when
40 available; Italy (600 heterozygotes harboring 76 unique missense variants), France (438
41 heterozygotes with 88 unique missense variants), and Japan (350 heterozygotes with 82 unique
42 missense variants). The literature data was reviewed to remove potential overlap of patients

43 between the cohort and literature set. The non-overlapping literature dataset and cohort set
44 were combined and optimism was estimated by 10-fold cross validation.

45
46 *KCNQ1 Variant Specific Features: Functional Data, Structural Data, and in silico Covariates.*
47 Functional data were collected from a previously assembled dataset of *KCNQ1* variant
48 functional data⁵, and from recent high-throughput automated patch clamp experiments^{6,7}. When
49 multiple functional measurements were available for a single variant, high-throughput
50 SyncroPatch measurements were given priority. A published cryo-EM model of *KCNQ1* enabled
51 high-resolution structural studies⁸. We applied our previously developed penetrance density
52 metric as a covariate in the *KCNQ1-LQT1* model (see previous manuscript for full description)⁵.
53 We obtained pathogenicity predictions using the *in silico* servers CardioBoost⁹, PolyPhen-2¹⁰,
54 and PROVEAN¹¹. Conservation scores were obtained by the basic local alignment search tool
55 position-specific scoring matrix (BLAST-PSSM) and point accepted mutation score. The meta-
56 predictor REVEL was additionally included given its previous impressive performance in similar
57 applications¹².

58
59 *Expectation-Maximization (EM) Algorithm.* The present EM algorithm comprises 2 steps: 1)
60 calculate the expected penetrance from an empirical Bayes penetrance model; 2) maximum
61 likelihood regression of estimated penetrance on variant-specific features. The EM algorithm
62 was performed using the covariates LQT1 probability density, CardioBoost, Provean, REVEL,
63 and homozygous peak current. The covariates were regressed to the fraction of heterozygous
64 carriers diagnosed with LQT1 using a logistic regression model. Missing data was handled
65 using a pattern mixture model, with a model fit for each missing data pattern. Full details of the
66 approach are described in the Supplementary Data (full code available on GitHub).

67

68 *Statistical evaluation.* All reported correlation coefficients, Spearman ρ , Pearson's R^2 , and
69 coefficient of determination were weighted by the function $1 - \frac{1}{0.01 + \text{total heterozygotes}}$, as
70 previously described^{3,4}, unless otherwise noted, to ensure variants with higher total
71 heterozygote counts had greater influence in the resulting correlation coefficient estimate. All
72 scripts and data used are available at the Kroncke Lab GitHub page. Additionally, a compiled
73 and curated form of the data presented here are available in the *KCNQ1* variant browser. We
74 performed 10-fold cross-validation using the caret package in R to create folds. All variants with
75 heterozygous carriers were included in the model. We calculated Spearman and Pearson
76 correlations between the Bayesian prior and Bayesian penetrance for each fold. We report
77 summary statistics for the average correlation coefficients and variances observed for 10
78 independent implementations of the 10-fold cross-fold validation. Brier scores were used as a
79 probabilistic classification metric as defined below:

80

81

$$\text{Brier Score} = \frac{1}{N} \sum_{t=1}^n (f_t - o_t)^2$$

82

83 Where N is the number of observations for a covariate, f_t is the probability of the covariate for
84 the t^{th} variant, and o_t is the observed penetrance for the t^{th} covariate.

85

86

87

88 **Supplemental Table 1.** Weighted Spearman and Pearson correlation coefficients and p-
89 values. Homozygous (hm); Heterozygous (ht).


90

Covariate	Weighted Spearman	Spearman p-Value	Weighted Pearson	Pearson p-Value	n
lqt1_dist	0.54	0	0.55	0	586
cardiacboost	0.65	0	0.59	0	582
hm_peak	-0.56	0	-0.53	0	143
hm_Vhalfact	0.43	0	0.38	0	102
hm_tauact	0.014	0.94	0.063	0.67	45
hm_taudeact	-0.24	0.076	-0.13	0.40	73
ht_peak	-0.55	0	-0.59	0	79
ht_Vhalfact	0.27	0.047	0.26	0.054	68
ht_tauact	0.044	0.81	-0.075	0.69	39
ht_taudeact	-0.27	0.13	-0.076	0.74	45
pph2_prob	0.54	0	0.42	0	586
provean_score	-0.62	0	-0.59	0	586
revel_score	0.64	0	0.62	0	586
blast_pssm	-0.26	0	-0.25	0	586
Bayes prior	0.71	0	0.70	0	586
Bayes posterior	0.95	0	0.95	0	586

91

92

93



94

95

96 **Supplemental Figure 1.** Observed Penetrance and Penetrance Density by Residue. Cartoon


97 schematic of the structure of KCNQ1 followed by empirical penetrance by residue (weighted

98 across all affected and total heterozygotes at each residue) and penetrance density as

99 described for the LQT1-dist covariate. Note smoothing of extremes in the LQT1 dist analysis.

100 Solid bars indicate 95% confidence intervals.

101



103

104 **Supplementary Figure 2.** Coverage plots for *KCNQ1-LQT1* model.


105 A) Tuning parameter of 1 is too stringent – more than 95% of values are above the 0.95
106 coverage rate.

107 B) Calibrated tuning parameter of 10 – approximately 95% of variants have a 0.95
108 coverage rate.

109 C) Overly permissible tuning parameter of 20 – less than 95% of variants have a
110 coverage rate less than 0.95.

111 D) Overly permissible tuning parameter of 50 – approximately half of variants have a
112 coverage rate less than 0.95.

113



114

115

116 **Supplementary Figure 3.** Coverage plots for *SCN5A-LQT3* model.

117 A) Tuning parameter of 1 is too stringent – more than 95% of values are above the 0.95
 118 coverage rate.

119 B) Calibrated tuning parameter of 5 – approximately 95% of variants have a 0.95
 120 coverage rate.

121 C) Overly permissible tuning parameter of 10 – less than 95% of variants have a
 122 coverage rate less than 0.95.

123 D) Overly permissible tuning parameter of 20 – approximately half of variants have a
124 coverage rate less than 0.95.

125

126 **Supplemental References**

127

128 1 Schwartz, P. J., Crotti, L. & Insolia, R. Long-QT syndrome: from genetics to management.
129 *Circ Arrhythm Electrophysiol* **5**, 868-877 (2012).

130 <https://doi.org:10.1161/circep.111.962019>

131 2 Priori, S. G. *et al.* HRS/EHRA/APHS expert consensus statement on the diagnosis and
132 management of patients with inherited primary arrhythmia syndromes: document
133 endorsed by HRS, EHRA, and APHS in May 2013 and by ACCF, AHA, PACES, and AEPC in
134 June 2013. *Heart Rhythm* **10**, 1932-1963 (2013).

135 <https://doi.org:10.1016/j.hrthm.2013.05.014>

136 3 Kozek, K. *et al.* Estimating the Post-Test Probability of Long QT Syndrome Diagnosis for
137 Rare KCNH2 Variants. *Circ Genom Precis Med* (2021).

138 <https://doi.org:10.1161/circgen.120.003289>

139 4 Kroncke, B. M. *et al.* A Bayesian method to estimate variant-induced disease
140 penetrance. *PLoS Genet* **16**, e1008862 (2020).

141 <https://doi.org:10.1371/journal.pgen.1008862>

142 5 Kroncke, B. M. *et al.* Protein structure aids predicting functional perturbation of
143 missense variants in SCN5A and KCNQ1. *Comput Struct Biotechnol J* **17**, 206-214 (2019).

144 <https://doi.org:10.1016/j.csbj.2019.01.008>

145 6 Glazer, A. M. *et al.* Arrhythmia variant associations and reclassifications in the eMERGE-
146 III sequencing study. *medRxiv*, 2021.2003.2030.21254549 (2021).

147 <https://doi.org:10.1101/2021.03.30.21254549>

148 7 Vanoye, C. G. *et al.* High-Throughput Functional Evaluation of KCNQ1 Decrypts Variants
149 of Unknown Significance. *Circ Genom Precis Med* **11**, e002345 (2018).

150 <https://doi.org:10.1161/circgen.118.002345>

151 8 Sun, J. & MacKinnon, R. Cryo-EM Structure of a KCNQ1/CaM Complex Reveals Insights
152 into Congenital Long QT Syndrome. *Cell* **169**, 1042-1050.e1049 (2017).

153 <https://doi.org:10.1016/j.cell.2017.05.019>

154 9 Zhang, X. *et al.* Disease-specific variant pathogenicity prediction significantly improves
155 variant interpretation in inherited cardiac conditions. *Genet Med* **23**, 69-79 (2021).

156 <https://doi.org:10.1038/s41436-020-00972-3>

157 10 Adzhubei, I. A. *et al.* in *Nat Methods* Vol. 7 248-249 (2010).

158 11 Choi, Y. & Chan, A. P. PROVEAN web server: a tool to predict the functional effect of
159 amino acid substitutions and indels. *Bioinformatics* **31**, 2745-2747 (2015).

160 <https://doi.org:10.1093/bioinformatics/btv195>

161 12 Ioannidis, N. M. *et al.* REVEL: An Ensemble Method for Predicting the Pathogenicity of
162 Rare Missense Variants. *Am J Hum Genet* **99**, 877-885 (2016).

163 <https://doi.org:10.1016/j.ajhg.2016.08.016>

164